Identification and evaluation of small molecule pan-caspase inhibitors in Huntington's disease models

Chemistry and Biology

Volumn 17, Issue 11, 2010, Pages 1189-1200

  Leyva, Melissa J ^a   Degiacomo, Francesco ^b   Kaltenbach, Linda S ^c   Holcomb, Jennifer ^b   Zhang, Ningzhe ^b   Gafni, Juliette ^b   Park, Hyunsun ^d   Lo, Donald C ^c   Salvesen, Guy S ^e   Ellerby, Lisa M ^b   Ellman, Jonathan A ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d CHDI MANAGEMENT CHDI FOUNDATION   (United States)

^e BURNHAM INSTITUTE   (United States)

^f YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 AMINO 4 METHYLCOUMARIN 3 ACETIC ACID; 7-AMINO-4-METHYLCOUMARIN-3-ACETIC ACID; CASPASE 3; CASPASE 6; COUMARIN DERIVATIVE; CYSTEINE PROTEINASE INHIBITOR; HDH PROTEIN, RAT; NERVE PROTEIN; NUCLEAR PROTEIN;

ANIMAL; APOPTOSIS; ARTICLE; CELL CULTURE; CHEMISTRY; CYTOLOGY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENZYME SPECIFICITY; GENETICS; HUMAN; HUNTINGTON CHOREA; METABOLISM; MOLECULAR LIBRARY; MOUSE; NERVE CELL; RAT; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; APOPTOSIS; CASPASE 3; CASPASE 6; CELLS, CULTURED; COUMARINS; CYSTEINE PROTEINASE INHIBITORS; DISEASE MODELS, ANIMAL; HUMANS; HUNTINGTON DISEASE; MICE; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; RATS; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

RATTUS;

EID: 78649341457     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2010.08.014     Document Type: Article

References (49)

1. M. Arrasate, S. Mitra, E.S. Schweitzer, M.R. Segal, and S. Finkbeiner Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death Nature 431 2004 805 810
2. E.S. Baskin-Bey, K. Washburn, S. Feng, T. Oltersdorf, D. Shapiro, M. Huyghe, L. Burgart, M. Garrity-Park, F.G.I. van Vilsteren, and L.K. Oliver Clinical trial of the pan-caspase inhibitor, IDN-6556, in human liver preservation injury Am. J. Transplant. 7 2007 218 225
3. J.G. Bieth Theoretical and practical aspects of proteinase inhibition kinetics Methods Enzymol. 248 1995 59 84
4. K. Brak, S. Doyle Patricia, H. McKerrow James, and A. Ellman Jonathan Identification of a new class of nonpeptidic inhibitors of cruzain J. Am. Chem. Soc. 130 2008 6404 6410
5. A. Brik, J. Alexandratos, Y.-C. Lin, H. Elder John, J. Olson Arthur, A. Wlodawer, S. Goodsell David, and C.-H. Wong 1,2,3-triazole as a peptide surrogate in the rapid synthesis of HIV-1 protease inhibitors ChemBioChem 6 2005 1167 1169
6. D. Charvin, E. Roze, V. Perrin, C. Deyts, S. Betuing, C. Pages, E. Regulier, R. Luthi-Carter, E. Brouillet, and N. Deglon Haloperidol protects striatal neurons from dysfunction induced by mutated huntingtin in vivo Neurobiol. Dis. 29 2008 22 29
7. M. Chen, V.O. Ona, M. Li, R.J. Ferrante, K.B. Fink, S. Zhu, J. Bian, L. Guo, L.A. Farrell, and S.M. Hersch Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease Nat. Med. 6 2000 797 801
8. S. Cornelis, K. Kersse, N. Festjens, M. Lamkanfi, and P. Vandenabeele Inflammatory caspases: targets for novel therapies Curr. Pharm. Des. 13 2007 367 385 (Pubitemid 46477759)
9. S.W. Davies, M. Turmaine, B.A. Cozens, M. DiFiglia, A.H. Sharp, C.A. Ross, E. Scherzinger, E.E. Wanker, L. Mangiarini, and G.P. Bates Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation Cell 90 1997 537 548
10. M. DiFiglia, E. Sapp, K.O. Chase, S.W. Davies, G.P. Bates, J.P. Vonsattel, and N. Aronin Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain Science 277 1997 1990 1993
11. A.W. Dunah, H. Jeong, A. Griffin, Y.-M. Kim, D.G. Standaert, S.M. Hersch, M.M. Mouradian, A.B. Young, N. Tanese, and D. Krainc Sp1 and TAFII 130 transcriptional activity disrupted in early Huntington's disease Science 296 2002 2238 2243
12. O.D. Ekici, Z.Z. Li, A.J. Campbell, K.E. James, J.L. Asgian, J. Mikolajczyk, G.S. Salvesen, R. Ganesan, S. Jelakovic, M.G. Grütter, and J.C. Powers Design, synthesis, and evaluation of aza-peptide Michael acceptors as selective and potent inhibitors of caspases-2, -3, -6, -7, -8, -9, and -10 J. Med. Chem. 49 2006 5728 5749
13. M.M.Y. Fan, H.B. Fernandes, L.Y.J. Zhang, M.R. Hayden, and L.A. Raymond Altered NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington's disease J. Neurosci. 27 2007 3768 3779
14. J. Gafni, and L.M. Ellerby Calpain activation in Huntington's disease J. Neurosci. 22 2002 4842 4849
15. J. Gafni, E. Hermel, J.E. Young, C.L. Wellington, M.R. Hayden, and L.M. Ellerby Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus J. Biol. Chem. 279 2004 20211 20220
16. F.G. Gervais, N.A. Thornberry, S.C. Ruffolo, D.W. Nicholson, and S. Roy Caspases cleave focal adhesion kinase during apoptosis to generate a FRNK-like polypeptide J. Biol. Chem. 273 1998 17102 17108
17. F.G. Gervais, D. Xu, G.S. Robertson, J.P. Vaillancourt, Y. Zhu, J. Huang, A. LeBlanc, D. Smith, M. Rigby, and M.S. Shearman Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation Cell 97 1999 395 406
18. Y.P. Goldberg, D.W. Nicholson, D.M. Rasper, M.A. Kalchman, H.B. Koide, R.K. Graham, M. Bromm, P. Kazemi-Esfarjani, N.A. Thornberry, J.P. Vaillancourt, and M.R. Hayden Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract Nat. Genet. 13 1996 442 449
19. R.K. Graham, Y. Deng, E.J. Slow, B. Haigh, N. Bissada, G. Lu, J. Pearson, J. Shehadeh, L. Bertram, and Z. Murphy Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin Cell 125 2006 1179 1191
20. C.-A. Gutekunst, S.-H. Li, H. Yi, J.S. Mulroy, S. Kuemmerle, R. Jones, D. Rye, R.J. Ferrante, S.M. Hersch, and X.-J. Li Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology J. Neurosci. 19 1999 2522 2534
21. HDCRG (The Huntington's Disease Collaborative Research Group) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes Cell 72 1993 971 983
22. E. Hermel, J. Gafni, S.S. Propp, B.R. Leavitt, C.L. Wellington, J.E. Young, A.S. Hackam, A.V. Logvinova, A.L. Peel, and S.F. Chen Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease Cell Death Differ. 11 2004 424 438
23. H. Inagaki, H. Tsuruoka, M. Hornsby, A. Lesley Scott, G. Spraggon, and A. Ellman Jonathan Characterization and optimization of selective, nonpeptidic inhibitors of cathepsin S with an unprecedented binding mode J. Med. Chem. 50 2007 2693 2699
24. L.S. Kaltenbach, M.M. Bolton, B. Shah, P.M. Kanju, G.M. Lewis, G.J. Turmel, J.C. Whaley, O.J. Trask Jr., and D.C. Lo Composite primary neuronal high-content screening assay for Huntington's disease incorporating non-cell-autonomous interactions Biomol. Screen 15 2010 806 819
25. S.H. Li, A.L. Cheng, H. Zhou, S. Lam, M. Rao, H. Li, and X.J. Li Interaction of Huntington disease protein with transcriptional activator Sp1 Mol. Cell. Biol. 22 2002 1277 1287
26. S.D. Linton, T. Aja, P.R. Allegrini, T.L. Deckwerth, J.-L. Diaz, B. Hengerer, J. Herrmann, K.G. Jahangiri, J. Kallen, and D.S. Karanewsky Oxamyl dipeptide caspase inhibitors developed for the treatment of stroke Bioorg. Med. Chem. Lett. 14 2004 2685 2691
27. S.D. Linton, T. Aja, R.A. Armstrong, X. Bai, L.S. Chen, N. Chen, B. Ching, P. Contreras, J.L. Diaz, and C.D. Fisher First-in-class pan caspase inhibitor developed for the treatment of liver disease J. Med. Chem. 48 2005 6779 6782
28. A. Lunkes, K.S. Lindenberg, L. Ben-Haiem, C. Weber, D. Devys, G.B. Landwehrmeyer, J.L. Mandel, and Y. Trottier Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions Mol. Cell 10 2002 259 269
29. D. Martindale, A. Hackam, A. Wieczorek, L. Ellerby, C. Wellington, K. McCutcheon, R. Singaraja, P. Kazemi-Esfarjani, R. Devon, and S.U. Kim Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates Nat. Genet. 18 1998 150 154
30. T. O'Brien, and D. Lee Prospects for caspase inhibitors Mini Rev. Med. Chem. 4 2004 153 165
31. A.W. Patterson, W.J.L. Wood, M. Hornsby, S. Lesley, G. Spraggon, and J.A. Ellman Identification of selective, nonpeptidic nitrile inhibitors of cathepsin S using the substrate activity screening method J. Med. Chem. 49 2006 6298 6307
32. C. Pop, and G.S. Salvesen Human caspases: activation, specificity, and regulation J. Biol. Chem. 284 2009 21777 21781
33. J.C. Reed Apoptosis-based therapies Nat. Rev. Drug Discov. 1 2002 111 121
34. J. Rozman-Pungercar, N. Kopitar-Jerala, M. Bogyo, D. Turk, O. Vasiljeva, I. Stefe, P. Vandenabeele, D. Broemme, V. Puizdar, and M. Fonovic Inhibition of papain-like cysteine proteases and legumain by caspase-specific inhibitors: when reaction mechanism is more important than specificity Cell Death Differ. 10 2003 881 888
35. H. Sawada, H. Ishiguro, K. Nishii, K. Yamada, K. Tsuchida, H. Takahashi, J. Goto, I. Kanazawa, and T. Nagatsu Characterization of neuron-specific huntingtin aggregates in human huntingtin knock-in mice Neurosci. Res. 57 2007 559 573
36. J.B. Schulz, M. Weller, R.T. Matthews, M.T. Heneka, P. Groscurth, J.C. Martinou, J. Lommatzsch, R. Von Coelln, U. Wullner, and P.A. Loschmann Extended therapeutic window for caspase inhibition and synergy with MK-801 in the treatment of cerebral histotoxic hypoxia Cell Death Differ. 5 1998 847 857
37. A. Schweizer, C. Briand, and M.G. Gruetter Crystal structure of xaspase-2, apical initiator of the intrinsic apoptotic pathway J. Biol. Chem. 278 2003 42441 42447
38. K.B. Sexton, M.D. Witte, G. Blum, and M. Bogyo Design of cell-permeable, fluorescent activity-based probes for the lysosomal cysteine protease asparaginyl endopeptidase (AEP)/legumain Bioorg. Med. Chem. Lett. 17 2007 649 653
39. E.C. Stack, A. Dedeoglu, K.M. Smith, K. Cormier, J.K. Kubilus, M. Bogdanov, W.R. Matson, L. Yang, B.G. Jenkins, and R. Luthi-Carter Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice J. Neurosci. 27 2007 12908 12915
40. H.R. Stennicke, and G.S. Salvesen Caspases: preparation and characterization Methods 17 1999 313 319
41. R.V. Talanian, C. Quinlan, S. Trautz, M.C. Hackett, J.A. Mankovich, D. Banach, T. Ghayur, K.D. Brady, and W.W. Wong Substrate specificities of caspase family proteases J. Biol. Chem. 272 1997 9677 9682
42. N.A. Thornberry, T.A. Rano, E.P. Peterson, D.M. Rasper, T. Timkey, M. Garcia-Calvo, V.M. Houtzager, P.A. Nordstrom, S. Roy, and J.P. Vaillancourt A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis J. Biol. Chem. 272 1997 17907 17911
43. S. Toulmond, K. Tang, Y. Bureau, H. Ashdown, S. Degen, R. O'Donnell, J. Tam, Y. Han, J. Colucci, and A. Giroux Neuroprotective effects of M826, a reversible caspase-3 inhibitor, in the rat malonate model of Huntington's disease Br. J. Pharmacol. 141 2004 689 697
44. F. Trettel, D. Rigamonti, P. Hilditch-Maguire, V.C. Wheeler, A.H. Sharp, F. Persichetti, E. Cattaneo, and M.E. MacDonald Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells Hum. Mol. Genet. 9 2000 2799 2809
45. C.L. Wellington, L.M. Ellerby, A.S. Hackam, R.L. Margolis, M.A. Trifiro, R. Singaraja, K. McCutcheon, G.S. Salvesen, S.S. Propp, and M. Bromm Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract J. Biol. Chem. 273 1998 9158 9167
46. C.L. Wellington, R. Singaraja, L. Ellerby, J. Savill, S. Roy, B. Leavitt, E. Cattaneo, A. Hackam, A. Sharp, and N. Thornberry Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells J. Biol. Chem. 275 2000 19831 19838
47. C.L. Wellington, L.M. Ellerby, C.A. Gutekunst, D. Rogers, S. Warby, R.K. Graham, O. Loubser, J. van Raamsdonk, R. Singaraja, and Y.Z. Yang Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease J. Neurosci. 22 2002 7862 7872
48. W.J.L. Wood, A.W. Patterson, H. Tsuruoka, R.K. Jain, and J.A. Ellman Substrate activity screening: a fragment-based method for the rapid identification of nonpeptidic protease inhibitors J. Am. Chem. Soc. 127 2005 15521 15527
49. W. Zhai, H. Jeong, L. Cui, D. Krainc, and R. Tjian In vitro analysis of Huntingtin-mediated transcriptional repression reveals multiple transcription factor targets Cell 123 2005 1241 1253